Patents by Inventor Robin Sherrington

Robin Sherrington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods For Identifying Analgesic Agents
    Publication number: 20160166541
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Application
    Filed: January 27, 2016
    Publication date: June 16, 2016
    Applicant: Xenon Pharmaceutical Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • Methods for identifying analgesic agents
    Patent number: 9278088
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: March 8, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • Methods for identifying analgesic agents
    Patent number: 9086420
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: July 21, 2015
    Assignee: Xenox Pharmaceuticals Inc.
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for Identifying Analgesic Agents
    Publication number: 20130210884
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Application
    Filed: April 11, 2013
    Publication date: August 15, 2013
    Applicant: Xenon Pharmaceutical Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • Methods for treating pain by inhibition of the SCN9A channel
    Patent number: 8410054
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: April 2, 2013
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for identifying analgesic agents
    Publication number: 20110306654
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Application
    Filed: May 27, 2011
    Publication date: December 15, 2011
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for identifying analgesic agents
    Publication number: 20100323359
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Application
    Filed: April 26, 2010
    Publication date: December 23, 2010
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for identifying analgesic agents
    Publication number: 20100076058
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 25, 2010
    Inventors: Marcia I. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for identifying analgesic agents
    Patent number: 7659082
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: February 9, 2010
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for identifying analgesic agents
    Publication number: 20070212685
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Application
    Filed: February 19, 2003
    Publication date: September 13, 2007
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Goldberg